<DOC>
	<DOC>NCT01369862</DOC>
	<brief_summary>The purpose of this phase I/II trial is to evaluate safety and tolerability of a single dose of GHB16L2 administered by liquid nasal spray for vaccination against seasonal influenza virus infection. It is also performed to assess immunogenicity and pharmacokinetics (shedding).</brief_summary>
	<brief_title>Study of Single Dose GHB16L2 Trivalent Influenza Vaccine in Healthy Adults</brief_title>
	<detailed_description>GHB16L2 intends to provide a novel vaccination for influenza virus infection. 80 healthy volunteers will be included at a ratio of 1:1 for GHB16L2 or placebo. GHB16L2 will be administered once on day 1. Follow-up visits will be performed on days 2, 8 and 29.</detailed_description>
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy male and female volunteers, 1860 years Seronegative for one or two of the applied vaccine strains Low antibody titres for H1N1v Written informed consent to participate in this study For female volunteers of childbearing potential, provision of a history and current use of reliable contraceptive practices Acute febrile illness (&gt;37.3°C) Signs of acute or chronic upper or lower tract respiratory illnesses History of severe atopy Seasonal influenza vaccination in 2008/2009 and/or later seasons and/or pandemic influenza vaccination at any time Fever ≥38.0°C in the time period between the prescreening visit and day 1 Known increased tendency of nose bleeding Volunteers with clinically relevant abnormal paranasal anatomy Volunteers with clinically relevant abnormal laboratory values In female volunteers of childbearing potential, a positive urine pregnancy test Simultaneous treatment with immunosuppressive drugs incl. Corticosteroids (≥2 weeks) within 4 weeks prior to study medication application Clinically relevant history of renal, hepatic, GI, cardiovascular, haematological, skin, endocrine, neurological or immunological diseases History of leukaemia or cancer HIV or Hepatitis B or C seropositivity Volunteers who underwent rhino or sinus surgery, or surgery of another traumatic injury of the nose within 30 days prior to application of study medication Volunteers who have received antiviral drugs, treatment with immunoglobulins or blood transfusions, or an investigational drug within 4 weeks prior to study medication application Volunteers who have received antiinflammatory drugs 2 days prior to study medication application Volunteers who are not likely to cope with the requirements of the study or with a significant physical or mental condition that may interfere with the completion of the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>live attenuated flu vaccines</keyword>
	<keyword>influenza A (H1N1)</keyword>
	<keyword>intranasal application</keyword>
	<keyword>replication-deficient influenza virus</keyword>
</DOC>